MX2024005546A - Conjugados que comprenden fosforo (v) y una fraccion molecular de droga. - Google Patents

Conjugados que comprenden fosforo (v) y una fraccion molecular de droga.

Info

Publication number
MX2024005546A
MX2024005546A MX2024005546A MX2024005546A MX2024005546A MX 2024005546 A MX2024005546 A MX 2024005546A MX 2024005546 A MX2024005546 A MX 2024005546A MX 2024005546 A MX2024005546 A MX 2024005546A MX 2024005546 A MX2024005546 A MX 2024005546A
Authority
MX
Mexico
Prior art keywords
drug moiety
conjugates
phosphorus
same
relates
Prior art date
Application number
MX2024005546A
Other languages
English (en)
Spanish (es)
Inventor
Jonas Helma-Smets
Dominik Schumacher
Christian Hackenberger
Marc- André KASPER
Philipp Ochtrop
Jahaziel Jahzerah
Paul Machui
Isabelle Mai
Original Assignee
Tubulis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tubulis Gmbh filed Critical Tubulis Gmbh
Publication of MX2024005546A publication Critical patent/MX2024005546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024005546A 2021-11-09 2022-11-09 Conjugados que comprenden fosforo (v) y una fraccion molecular de droga. MX2024005546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207195 2021-11-09
PCT/EP2022/081345 WO2023083900A1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety

Publications (1)

Publication Number Publication Date
MX2024005546A true MX2024005546A (es) 2024-07-10

Family

ID=78592631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005546A MX2024005546A (es) 2021-11-09 2022-11-09 Conjugados que comprenden fosforo (v) y una fraccion molecular de droga.

Country Status (15)

Country Link
US (2) US20230330258A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429708A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540691A (cg-RX-API-DMAC7.html)
KR (1) KR20240100413A (cg-RX-API-DMAC7.html)
CN (1) CN118302197A (cg-RX-API-DMAC7.html)
AU (1) AU2022385379A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237371A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001372A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005877A2 (cg-RX-API-DMAC7.html)
DE (1) DE22817174T1 (cg-RX-API-DMAC7.html)
ES (1) ES2999335T1 (cg-RX-API-DMAC7.html)
IL (1) IL312675A (cg-RX-API-DMAC7.html)
MX (1) MX2024005546A (cg-RX-API-DMAC7.html)
PE (1) PE20242107A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023083900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321506A (en) * 2022-12-22 2025-08-01 Tubulis Gmbh Conjugates comprising a phosphorus(v) moiety and a drug
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
KR20260065883A (ko) 2023-09-01 2026-05-11 투불리스 게엠베하 포스포나미데이트 화합물의 제조 방법
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026096695A1 (en) 2024-10-31 2026-05-07 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates
WO2026107136A1 (en) 2024-11-14 2026-05-21 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates for the treatment of cancer
WO2026105061A1 (en) 2024-11-15 2026-05-21 Pheon Therapeutics Ltd Antibody-drug conjugates that bind cdcp1 and uses thereof
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
WO2018041985A1 (en) 2016-09-01 2018-03-08 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
US12453779B2 (en) 2018-03-07 2025-10-28 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物

Also Published As

Publication number Publication date
AU2022385379A1 (en) 2024-06-20
US20250281634A1 (en) 2025-09-11
CO2024005877A2 (es) 2024-07-08
DE22817174T1 (de) 2024-12-12
KR20240100413A (ko) 2024-07-01
CA3237371A1 (en) 2023-05-19
CN118302197A (zh) 2024-07-05
ES2999335T1 (en) 2025-02-25
CL2024001372A1 (es) 2024-10-25
JP2024540691A (ja) 2024-10-31
EP4429708A1 (en) 2024-09-18
IL312675A (en) 2024-07-01
US20230330258A1 (en) 2023-10-19
WO2023083900A1 (en) 2023-05-19
PE20242107A1 (es) 2024-10-28

Similar Documents

Publication Publication Date Title
MX2024005545A (es) Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina.
CL2024001372A1 (es) Conjugados que comprenden fósforo (v) y una fracción molecular de droga
ES2898315T3 (es) Preparación de nicotina racémica mediante reacción de nicotinato de etilo con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores
NZ588851A (en) Potent conjugates and hydrophilic linkers
MX2023015423A (es) Ligando de acido nucleico y conjugado, metodo de preparacion y uso del mismo.
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
MX2013014583A (es) Conjugados de proteina-polimero-farmaco.
WO2010033733A4 (en) Folate receptor binding conjugates of antifolates
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
WO2009095479A3 (en) Prodrug comprising a self-cleavable linker
MY197127A (en) Pyrrolobenzodiazepine conjugates
MX2025012396A (es) Conjugados que comprenden enlazadores escindibles
MX2026001691A (es) Conjugados que comprenden enlazadores escindibles
MX2022009052A (es) Compuestos y conjugados de estos.
WO2024238872A3 (en) Isoindolinone-glutarimide antibody conjugates, and uses thereof
NZ593438A (en) Synthesis of polymer conjugates of indolocarbazole compounds
WO2022115944A8 (en) Carboxylated psilocybin derivatives and methods of using
WO2023086028A3 (en) Allenamide linkers for antibody-drug conjugate
WO2022125891A3 (en) Anti-cea immunoconjugates, and uses thereof
UA100862C2 (ru) Шестичленные ароматические соединения, их получение и применение (варианты)
WO2026006688A3 (en) Degrader antibody conjugates and uses thereof
MX2023001679A (es) Inmunoconjugados de pirazolazepina y usos de estos.
WO2008059513A3 (en) Compounds suitable as modulators of hdl
IL172710A0 (en) Tacrine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW200726752A (en) Process for the production of intermediates for the preparation of tricyclic benzimidazoles